GET DAILY SIGNALSEli Lilly (LLY): Is +17% Upside to the $1,580 Target Realistic?
Key Takeaways
- The $1,580 central target is the arithmetic mean of 17 recently updated, individually attributed analyst price targets, most issued after late-October 2026 earnings.
- With the stock near $1,354, reaching $1,580 would require a rise of roughly 17%, a substantial move from current levels.
- Among the reviewed targets, the range runs from $1,400 to $1,650; the broader sell-side range extends from a bearish $940 (HSBC, Sell) to about $1,690.
- Support comes from surging GLP-1 demand, raised full-year revenue guidance, and a deep late-stage pipeline, including retatrutide and the oral therapy Foundayo.
- Key risks are a premium valuation, growing competition in obesity care, pricing pressure, and concentration of growth in two franchises.
- For more detail on this name, explore its Major News, Today's Price Move, Forecast, and Earnings pages.
- Investors looking for AI-driven market insight can also explore Trending AI Robots.
What Analysts Are Saying About LLY
The $1,580 central target reflects a review of 17 current analyst price targets attributable to specific firms, most refreshed around the company's third-quarter results. Targets cluster tightly between roughly $1,400 and $1,650, with BMO Capital, Citi, and JPMorgan near $1,650 and Berenberg at $1,400 after its upgrade to Buy. The calculated average of these 17 figures is about $1,581, rounded to $1,580. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
The wider analyst universe is more dispersed. Independent aggregators report a consensus rating of Buy to Strong Buy across roughly 30-plus analysts, with a mean near $1,450 and a range spanning from HSBC's $940 Sell target to highs around $1,690. The gap reflects genuine disagreement about how much of Lilly's long-term growth is already reflected in the share price.
Recent revisions have been decidedly upward. Following the Q3 report, Cantor Fitzgerald and RBC Capital moved to $1,600, Truist to $1,612, Jefferies to $1,610, UBS to $1,625, and Scotiabank to $1,605, while Morgan Stanley and Goldman Sachs lifted targets to $1,596 and $1,573, respectively. The dominant rationale is continued GLP-1 momentum and confidence that Lilly can hold its obesity and diabetes leadership.
LLY's Current Position and Growth Drivers
The stock closed near $1,354, leaving roughly 17% upside to the $1,580 target, a substantial move for a company of this size. Lilly's third-quarter results reinforced the growth narrative: revenue rose about 39% to $24.4 billion, with Mounjaro sales up roughly 65% and Zepbound up about 49%, while adjusted earnings of $7.48 per share (EPS) topped the roughly $5.38 consensus estimate. Management raised full-year revenue guidance to $91 billion–$92 billion.
The path to $1,580 would most plausibly run through sustained franchise growth, successful launches of Foundayo and retatrutide, and pipeline execution across oncology and neuroscience. The stock trades at roughly 44 times trailing earnings, a rich multiple that means upside depends on earnings catching up to valuation rather than further multiple expansion alone.
Factors That Could Drive Shares Higher
Demand for Mounjaro and Zepbound remains the core engine, and analysts point to the Medicare Bridge program as a driver of broader obesity-drug access. The expected diabetes approval of Foundayo, an oral GLP-1, and late-stage data on retatrutide offer additional catalysts. Lilly has also been active in business development, completing multiple acquisitions to broaden its pipeline, and its raised full-year guidance signals management confidence in near-term growth.
Risks to Consider
The most visible obstacle is valuation. At a premium to the broader market, the stock has little room for error if growth slows or expectations reset. Competition from Novo Nordisk and a growing field of GLP-1 challengers, alongside political and pricing pressure on obesity medicines, could compress both sales and the multiple. Because so much of Lilly's value rests on two franchises, any supply, safety, or competitive setback there would weigh disproportionately on the shares.
Technical Picture and Support Levels
Lilly recently set an all-time high near $1,453 before pulling back, making that level the key resistance to clear on any move toward $1,580. The shares found support around $1,330 in early November, with the psychological $1,300 area and the late-October breakout zone below that acting as secondary floors. The stock remains in a long-term uptrend well above its 52-week low near $850.
What to Watch Going Forward
Analyst price targets typically reflect a roughly 12-month research horizon, though individual firms vary. Investors should watch quarterly GLP-1 sales trends, the Foundayo approval and launch trajectory, retatrutide data, full-year guidance updates, and any shifts in Medicare coverage or drug-pricing policy. Analyst revisions and competitive data from rival obesity programs are also worth tracking.
AI Daily Buy/Sell Signals
In my own work, I often rely on Tickeron’s AI Daily Buy/Sell Signals to stay on top of momentum shifts in names like this. The tool applies artificial intelligence to scan thousands of stocks and ETFs in real time, delivering Buy, Sell, or Hold signals based on technical behavior and market conditions. It helps me quickly spot changes that might otherwise require manual chart reviews, which is especially useful when following large-cap healthcare stocks alongside fundamental research.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
LLY's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for LLY turned positive on October 07, 2026. Looking at past instances where LLY's MACD turned positive, the stock continued to rise in 36 of 44 cases over the following month. The odds of a continued upward trend are 82%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 14, 2026. You may want to consider a long position or call options on LLY as a result. In 55 of 81 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 68%.
LLY moved above its 50-day moving average on October 14, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for LLY crossed bullishly above the 50-day moving average on October 15, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 9 of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 69%.
Following a +10.03% 3-day Advance, the price is estimated to grow further. Considering data from situations where LLY advanced for three days, in 258 of 371 cases, the price rose further within the following month. The odds of a continued upward trend are 70%.
The Aroon Indicator entered an Uptrend today. In 216 of 297 cases where LLY Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 73%.
Bearish Trend Analysis
The 10-day RSI Indicator for LLY moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 34 similar instances where the indicator moved out of overbought territory. In 23 of the 34 cases, the stock moved lower in the following days. This puts the odds of a move lower at 68%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 40 of 64 cases where LLY's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 62%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where LLY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 54%.
LLY broke above its upper Bollinger Band on October 29, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 4 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 59, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 7 (best 1 - 100 worst), indicating outstanding price growth. LLY’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 14 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 48 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 86 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: LLY's P/B Ratio (35.624) is slightly higher than the industry average of (-1.421). P/E Ratio (45.360) is within average values for comparable stocks, (21.700). Projected Growth (PEG Ratio) (1.170) is also within normal values, averaging (5.738). Dividend Yield (0.005) settles around the average of (0.038) among similar stocks. LLY's P/S Ratio (12.804) is very high in comparison to the industry average of (4.033).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of pharmaceutical products
Industry PharmaceuticalsMajor
Advertisement